Analysis of Health Care Costs in Elderly Patients with Multiple Chronic Conditions Using a Finite Mixture of Generalized Linear Models

2016 ◽  
Vol 26 (5) ◽  
pp. 582-599 ◽  
Author(s):  
Matthias Eckardt ◽  
Christian Brettschneider ◽  
Hendrik van den Bussche ◽  
Hans-Helmut König ◽  
Keyword(s):  
Health Care ◽  
Elderly Patients ◽  
Health Care Costs ◽  
Generalized Linear Models ◽  
Chronic Conditions ◽  
Linear Models ◽  
Finite Mixture ◽  
Multiple Chronic Conditions ◽  
Care Costs

scholarly journals Institutionalization-Free Survival and Health Care Costs among Quebec Community-Dwelling Elderly Patients with Dementia

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Sarah-Gabrielle Beland ◽  
Antoine Pariente ◽  
Yola Moride
Keyword(s):  
Health Care ◽  
Elderly Patients ◽  
Health Care Costs ◽  
Reference Population ◽  
Community Dwelling ◽  
Third Party ◽  
Published Data ◽  
Administrative Claims ◽  
Free Survival ◽  
Care Costs

Background. Published data on burden of dementia mainly include patients of third-care facilities. Economic consequences in an outpatient setting remain poorly examined. Objectives. To evaluate institutionalization-free survival and direct health care costs of dementia in the Quebec community-dwelling elderly population. Methods. A retrospective cohort study was conducted using the Quebec administrative claims databases. The cohort included a random sample of patients with treated dementia between January 1, 2000, and December 31, 2009 (n=37,138). The reference population included elderly patients without dementia matched in age group, gender, and index date. Using a third-party payer perspective, direct costs over 5 years were assessed. Results. Institutionalization-free survival at 5 years was lower in patients with dementia than in elderly without dementia (38.9% and 72.2%, resp.). Over 5 years, difference in mean total direct health care costs per patient was CAD$19,159, distributed into institutionalizations (CAD$13,598), hospitalizations (CAD$3,312), and prescribed medications (CAD$2,320). Costs of medical services were similar (−CAD$96). In the first year of followup, cost differentials were mainly attributable to hospitalizations, while in the last year (year 5) they were due to institutionalizations. Conclusion. This study confirms that dementia is an important socioeconomic burden in the community, the nature of which depends on disease progression.

Disease-Related and All-Cause Health Care Costs of Elderly Patients With Gout

2008 ◽  
Vol 14 (2) ◽  
pp. 164-175 ◽  
Author(s):  
Eric Q. Wu ◽  
Pankaj A. Patel ◽  
Andrew P. Yu ◽  
Reema R. Mody ◽  
Kevin E. Cahill ◽  
...  
Keyword(s):  
Health Care ◽  
Elderly Patients ◽  
Health Care Costs ◽  
Care Costs

scholarly journals Healthcare utilisation after discharge in patients admitted with gout in Western Australia

2021 ◽  
Author(s):  
Erin Kelty ◽  
Philip Robinson ◽  
Catherine Hill ◽  
Johannes Nossent ◽  
Warren Raymond ◽  
...  
Keyword(s):  
Health Care ◽  
Health Service ◽  
Health Care Costs ◽  
Linear Models ◽  
Hospital Admissions ◽  
Healthcare Utilisation ◽  
Health Service Utilisation ◽  
Service Utilisation ◽  
Median Cost ◽  
Care Costs

Abstract Objectives Evidence suggests that gout is associated with high health care costs and that many inpatient admissions are preventable. Understanding the drivers of health care costs in patients with gout will allow more targeted intervention. The objective was to examine factors associated with high health service utilisation and costs in patients admitted to hospital with gout. Methods Hospital and emergency department data was obtained for patients who had been admitted to hospital with a diagnosis of gout for the first time between 2002 and 2009. The total number, cost and potentially preventable events for the follow-up period was calculated for up to five years post the initial gout hospitalisation. The association between patient characteristics with health service utilisation and health care costs was examined using generalised linear models. Results The cohort included 4,379 individuals, that had 22,222 ED attendances (median cost: $1,826 per patient, IQR: $433 - $4,414), and 58,920 hospital admissions (median cost: $25,009 per patient, IQR: $6,844 - $60,535). Gout was not a primary driver of ED attendances or hospitalisations. A history of smoking and comorbidities including cardiovascular disease, diabetes and mental health disorders were associated with an increase health service utilisation and costs. Conclusion The presence of comorbidities play an important role the risk of health service utilization in people with gout and represents an opportunity to both improve the health-related outcomes for these patients and reduce re-presentations and associated health care costs for the health care system.

scholarly journals Health Care Costs Associated with Ankylosing Spondylitis in Turkey: An Analysis from Nationwide Real-World Data

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Onur Baser ◽  
Abdulkadir Burkan ◽  
Erdem Baser ◽  
Rasim Koselerli ◽  
Emre Ertugay ◽  
...  
Keyword(s):  
Health Care ◽  
Ankylosing Spondylitis ◽  
Health Care Costs ◽  
Linear Models ◽  
Office Visit ◽  
Real World Data ◽  
Treatment Type ◽  
Comorbidity Scores ◽  
Incident Cases ◽  
Care Costs

Objectives. To explore health care costs associated with ankylosing spondylitis (AS) in Turkey.Methods. Research-identified data from a system that processes claims for all Turkish health insurance funds were analyzed. Adult prevalent and incident AS patients with two AS visits at least 60 days apart, identified between June 1, 2010 and December 31, 2010, with at least 1 year of continuous health plan enrollment for the baseline and follow-up years were included in the study. Pharmacy, outpatient, and inpatient claims were compiled over the study period for the selected patients. Generalized linear models were used to estimate the expected annual costs, controlling for baseline demographic and clinical characteristics.Results. A total of 2.986 patients were identified, of which 603 were incident cases and 2.383 prevalent cases. The mean ages were 39 and 41 years, respectively, and 44% and 38% were women for incident and prevalent cases. Prevalent patients had higher comorbidity scores (5.01 versus 2.24,P<0.001) and were more likely to be prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) (77% versus 72%,P<0.001) or biologics (35% versus 8%,P<0.006) relative to incident patients. Seventy-seven percent of prevalent patients were prescribed NSAIDs, followed by biologic and disease-modifying antirheumatic drugs (DMARDs). Total annual medical costs for incident AS patients were €2.253 and €4.233 for prevalent patients. Pharmacy costs accounted for a significant portion of total costs (88% for prevalent patient, 77% for incident patient), followed by physician office visit costs. Prior comorbidities and treatment type also significantly contributed to overall costs.Conclusion. Annual expenditures for AS patients in Turkey were comparable relative to European countries. Pharmaceutical expenditures cover a significant portion of the overall costs. Comparative effectiveness studies are necessary to further decrease health care costs of AS treatment.

Sign in / Sign up

Export Citation Format

Share Document